Nurix Therapeutics, Inc. NRIX Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Nurix Therapeutics, Inc. (NRIX) reported cash, cash equivalents, and marketable securities of $151.57M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Nurix Therapeutics, Inc.'s cash, cash equivalents, and marketable securities increased by 61.3% year-over-year, from $93.94M to $151.57M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.